company background image
A068

Celltrion Pharm KOSDAQ:A068760 Stock Report

Last Price

₩77.60k

Market Cap

₩2.8t

7D

-5.9%

1Y

-40.4%

Updated

17 May, 2022

Data

Company Financials
A068760 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health4/6
Dividends0/6

A068760 Stock Overview

Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea.

Celltrion Pharm Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Celltrion Pharm
Historical stock prices
Current Share Price₩77,600.00
52 Week High₩174,466.02
52 Week Low₩72,300.00
Beta0.63
1 Month Change-11.42%
3 Month Change-10.18%
1 Year Change-40.44%
3 Year Change70.19%
5 Year Change347.77%
Change since IPO512.05%

Recent News & Updates

May 05
Does Celltrion Pharm (KOSDAQ:068760) Deserve A Spot On Your Watchlist?

Does Celltrion Pharm (KOSDAQ:068760) Deserve A Spot On Your Watchlist?

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...

Mar 03
Do Institutions Own Celltrion Pharm, Inc. (KOSDAQ:068760) Shares?

Do Institutions Own Celltrion Pharm, Inc. (KOSDAQ:068760) Shares?

If you want to know who really controls Celltrion Pharm, Inc. ( KOSDAQ:068760 ), then you'll have to look at the makeup...

Feb 02
These 4 Measures Indicate That Celltrion Pharm (KOSDAQ:068760) Is Using Debt Reasonably Well

These 4 Measures Indicate That Celltrion Pharm (KOSDAQ:068760) Is Using Debt Reasonably Well

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Dec 29
Do Celltrion Pharm's (KOSDAQ:068760) Earnings Warrant Your Attention?

Do Celltrion Pharm's (KOSDAQ:068760) Earnings Warrant Your Attention?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Shareholder Returns

A068760KR PharmaceuticalsKR Market
7D-5.9%0.03%0.006%
1Y-40.4%-27.6%-15.8%

Return vs Industry: A068760 underperformed the KR Pharmaceuticals industry which returned -27.6% over the past year.

Return vs Market: A068760 underperformed the KR Market which returned -15.8% over the past year.

Price Volatility

Is A068760's price volatile compared to industry and market?
A068760 volatility
A068760 Average Weekly Movement6.3%
Pharmaceuticals Industry Average Movement4.4%
Market Average Movement5.5%
10% most volatile stocks in KR Market10.3%
10% least volatile stocks in KR Market3.2%

Stable Share Price: A068760 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: A068760's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1976n/aJung-su Seohttps://www.celltrionph.com

Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies.

Celltrion Pharm Fundamentals Summary

How do Celltrion Pharm's earnings and revenue compare to its market cap?
A068760 fundamental statistics
Market Cap₩2.83t
Earnings (TTM)₩26.03b
Revenue (TTM)₩274.73b

112.0x

P/E Ratio

10.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A068760 income statement (TTM)
Revenue₩274.73b
Cost of Revenue₩193.89b
Gross Profit₩80.84b
Other Expenses₩54.82b
Earnings₩26.03b

Last Reported Earnings

Mar 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)692.73
Gross Margin29.43%
Net Profit Margin9.47%
Debt/Equity Ratio63.0%

How did A068760 perform over the long term?

See historical performance and comparison

Valuation

Is Celltrion Pharm undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


112.02x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate A068760's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A068760's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: A068760 is poor value based on its PE Ratio (112x) compared to the KR Pharmaceuticals industry average (25.3x).

PE vs Market: A068760 is poor value based on its PE Ratio (112x) compared to the KR market (14.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A068760's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: A068760 is overvalued based on its PB Ratio (9.6x) compared to the KR Pharmaceuticals industry average (1.7x).


Future Growth

How is Celltrion Pharm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


19.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Celltrion Pharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Celltrion Pharm performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


146.8%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: A068760 has high quality earnings.

Growing Profit Margin: A068760's current net profit margins (9.5%) are higher than last year (5.9%).


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if A068760's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare A068760's past year earnings growth to its 5-year average.

Earnings vs Industry: A068760 earnings growth over the past year (146.8%) exceeded the Pharmaceuticals industry -15.5%.


Return on Equity

High ROE: A068760's Return on Equity (8.6%) is considered low.


Financial Health

How is Celltrion Pharm's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: A068760's short term assets (₩257.2B) exceed its short term liabilities (₩208.3B).

Long Term Liabilities: A068760's short term assets (₩257.2B) exceed its long term liabilities (₩61.9B).


Debt to Equity History and Analysis

Debt Level: A068760's net debt to equity ratio (51.5%) is considered high.

Reducing Debt: A068760's debt to equity ratio has reduced from 67.7% to 63% over the past 5 years.

Debt Coverage: A068760's debt is not well covered by operating cash flow (14.9%).

Interest Coverage: A068760's interest payments on its debt are well covered by EBIT (6.7x coverage).


Balance Sheet


Dividend

What is Celltrion Pharm current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A068760's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A068760's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A068760's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A068760's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A068760 has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Jung-su Seo

no data

Tenure

Jung-su Seo is Chief Executive Officer and Internal Director of Celltrion Pharm, Inc.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Celltrion Pharm, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Celltrion Pharm, Inc.
  • Ticker: A068760
  • Exchange: KOSDAQ
  • Founded: 1976
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₩2.829t
  • Shares outstanding: 37.57m
  • Website: https://www.celltrionph.com

Location

  • Celltrion Pharm, Inc.
  • 82, 2sandan-ro
  • Ochang-eup
  • Cheongju
  • Chungcheongbuk-do
  • South Korea

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/17 00:00
End of Day Share Price2022/05/17 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.